Action of raloxifene on the biology of breast cancer prevention
ABSTRACT. Introduction: Raloxifene is an estrogen receptor modulator that competes with estrogens for binding to the estrogen receptor. Based on the results of the STAR study of tamoxifen and raloxifene, raloxifene has been approved by the US Food and Drug Administration for the reduction of BC breast cancer risk. A statistically significant reduction was observed in cases of estrogen receptor positive invasive breast cancer in women in the raloxifene group compared to the placebo group. When only cases of tumors with positive estrogen receptors were analyzed, the Raloxifene relative risk reduction reduced the incidence of the primary outcome of invasive breast cancer, the Hazard Ratio, 0.56, and the Confidence Interval, 0.38. 83, and B, mainly because a. In a study of women at high risk for breast cancer, scientists discovered that women who took tamoxifen for years had less breast cancer than women who took a placebo. Although tamoxifen can prevent primary breast cancer, few women use it as a preventive measure. A second option, raloxifene, has recently been approved. The purpose of the study was to determine women's interest in tamoxifen and raloxifene after reading a decision aid describing the risks and benefits of each drug; Request PDF, Role of raloxifene in the prevention of breast cancer in postmenopausal women: clinical evidence and potential mechanisms of action. Raloxifene is a selective estrogen receptor modulator. Information about dosage of raloxifene. Usual Adult Dose for Osteoporosis: Oral Daily Notes: Advise patients to supplement with calcium and/or vitamin D for the treatment or prevention of osteoporosis if daily intake is insufficient. - When this drug is used to reduce the risk of invasive breast cancer, it is optimal. The duration of treatment is: The pharmacodynamic properties of raloxifene have been previously discussed6,7 and its mechanism of action has been discussed in detail elsewhere. This section briefly describes the mechanism of action of raloxifene and discusses its effects on breast tissue, markers of breast cancer risk, endometrium, bone, lipids. It is used to treat or prevent soft, brittle bones. menopause change of life. It is used to help prevent breast cancer after menopause in people with soft, brittle bones, osteoporosis, or in people at increased risk of developing breast cancer. It may be given to you for other reasons. Raloxifene hydrochloride reduced the incidence of invasive breast cancer compared to placebo in 1 woman-year. This was mainly due to the reduction in the incidence of ER-positive invasive breast cancer in the raloxifene hydrochloride group compared to placebo. presents the efficacy and selected, A. Diet modification. Obesity is a common cause of many cancers, including those of the breast, endometrium, ovaries, prostate, liver, gallbladder, kidney and colon. How specific foods affect breast cancer risk, independent of weight gain or loss, is less certain. Obesity is associated with a higher risk of premenopause. Over the years, tamoxifen has proven effective in treating women with breast cancer and in preventing breast cancer in women at high risk 59. In contrast to tamoxifen, clinical experience with raloxifene is limited. Raloxifene showed antitumor properties in women with breast cancer,